Conference
Long term follow-up of liver transplant recipients after allogeneic mesenchymal stromal cell infusion
| العنوان: | Long term follow-up of liver transplant recipients after allogeneic mesenchymal stromal cell infusion |
|---|---|
| المؤلفون: | VANDERMEULEN, Morgan, Mohamed Wais, M, DELBOUILLE, Marie-Hélène, MAGGIPINTO, Gianni, BEGUIN, Yves, DETRY, Olivier |
| المصدر: | Transplant International, 34 (S1 OP282), 45 (2021-08); ESOT 2021, Milan, Italy [IT], Du 29 aout au 1 septembre 2021 |
| بيانات النشر: | Blackwell, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Human health sciences, Surgery, Gastroenterology & hepatology, Sciences de la santé humaine, Chirurgie, Gastroentérologie & hépatologie |
| الوصف: | Background: Some properties of mesenchymal stromal cells (MSCs) mightbe particularly of interest after organ transplantation. The authors aimed toreport herein the long-term results of their first-in man, prospective, controlled,phase-1 study evaluating the safety of a single third-party MSC infusionafter liver transplantation (LT).Methods: Ten liver transplant recipients under standard immunosuppressionreceived 1.5–3 9 106/kg unrelated third-party MSCs on post-operativeday 3 ! 2 and were prospectively compared to a control group of 10 livertransplant recipients. Primary endpoints were set to prospectively detectpotential delayed side effects of MSC infusion, and particularly occurrenceof infections and cancers. As secondary endpoints, liver graft- and patientsurvivals, graft rejection and function, occurrence of bile duct complications,and development of anti-HLA antibodies against liver- or MSC-donors werestudied.Results: There was no difference in overall rates of infection or cancer at 5years of follow-up between the two groups. There was also no difference inliver graft- and patient survivals, graft rejection, blood liver tests or occurrenceof bile duct complications. The prevalence of de novo liver DSArelated to HLA-mismatches was two times higher in the MSC group comparedto the control group. Three patients of the MSC group (30%) developedat least 1 de novo HLA antibody against MSC-donor. All the de novoclass II HLA antibodies against MSC were linked to a shared HLA mismatchbetween the liver and MSC donors and 75% of HLA class II shared-mismatchesled to de novo HLA antibodies.Conclusions: This long-term follow-up confirms the safety of one singleMSC infusion after LT. The potential interesting effects of MSC need to beconfirmed by prospective studies. The development of anti-HLA antibodiesagainst MSC donor should be further evaluated especially in case of sharedHLAmismatchesbetween graft- and MSC-donors, despite the fact that nodeleterious effect could be detected. |
| نوع الوثيقة: | conference paper http://purl.org/coar/resource_type/c_5794 conferenceObject peer reviewed |
| اللغة: | English |
| Relation: | urn:issn:0934-0874; urn:issn:1432-2277 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/262821 |
| Rights: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.262821 |
| قاعدة البيانات: | ORBi |
| الوصف غير متاح. |